Dear User,
On May 25, 2018, Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 (General Data Protection Regulation) came into force. We encourage you to familiarise yourself with information about the processing of personal data on the PolskieRadio.pl website.
1.The Data Administrator is Polish Radio S.A., based at 77/85 Niepodległości Ave., 00-977, Warsaw.
2.On issues regarding your data, please contact the Data Protection Officer, e-mail: iod@polskieradio.pl, tel. 22 645 34 03.
3.Personal data may be processed for marketing purposes based on consent.
4.Personal data may be shared solely for the purpose of proper implementation of services defined in the privacy policy.
5.Personal data will not be transferred outside the European Economic Area or to an international organisation.
6.Personal data will be stored for 5 years after an account is deactivated, in accordance with the law.
7.You have the right to access your personal data, correct it, to have it moved or deleted, or to limit its processing.
8.You have the right to object to further processing, and in the case of voicing consent to the processing of personal data, you have the right to withdraw your consent. The exercise of the right to withdraw consent does not affect any processing that has already taken place.
9.You have the right to lodge a complaint with the supervisory authority.
10.Polish Radio S.A. declares that no automated decisions are made when personal data is processed, and that profiling is not used.
For more information on this subject, please read our personal data and privacy policy.
English Section

European regulator gives green light for Astra-Oxford COVID-19 vaccine (REUTERS)

29.01.2021 18:45
Europe's medicines regulator on Friday approved AstraZeneca and Oxford University's COVID-19 vaccine for people over the age of 18, the third vaccine to be cleared for use in the European Union.

The AstraZeneca vaccine demonstrated an efficacy of around 60% in the trials on which the decision was based, the European Medicines Agency (EMA) said in a statement.

That is well below the level of protection shown by authorised vaccines from Pfizer and its German partner BioNTech and rival Moderna, which were around 95% effective in preventing symptomatic illness in pivotal trials.

“With this third positive opinion, we have further expanded the arsenal of vaccines available to EU and EEA member states to combat the pandemic and protect their citizens,” said Emer Cooke, Executive Director of EMA.

The European Union last year agreed to buy up to 400 million doses of the vaccine and has been at the centre of a dispute with AstraZeneca this week over the speed of supplies.

Europe urgently needs more shots to speed up its inoculation programme with Pfizer and Moderna also facing difficulties in delivering the quantities promised for the early months of the year.

The AstraZeneca vaccine is cheaper and easier to store than the two already approved from Pfizer and Moderna.

AstraZeneca CEO Pascal Soriot welcomed the decision. "Today’s recommendation underscores the value of AstraZeneca’s COVID-19 vaccine which is not only effective and well-tolerated, but also easy to administer and, importantly, protects fully against severe disease and hospitalisations," he said in a statement.

The AstraZeneca vaccine is administered via two injections into the arm, the second between 4 and 12 weeks after the first.

There were not yet enough results for people over the age of 55 to determine how well the vaccine would work for this group, EMA said.

However, it said that the vaccine can be given to older people. "At least some protection is expected in this subgroup, although the exact level of protection cannot be estimated for the time being," Bruno Sepodes, vice chair of EMA's human medicines committee, told a briefing.

Concerns over its value for the elderly were raised on Thursday when Germany's vaccine committee said it should be given only to people aged between 18 and 64, due to a lack of data about how effective it is in older people.

Antonella Viola, professor of immunology at Italy's University of Padua, was sceptical about the vaccine.

"60% efficacy with a double dose and with doubts for the age group over 55 years.... Herd immunity will never be achieved with this vaccine, it's mathematical," she said. "I would only use it for younger people at most".

By Ludwig Burger and Pushkala Aripaka (Reuters)